TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00692055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN400
Description: naproxen 375 mg / esomeprazole 20 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: naproxen 375 mg
Study: NCT00919893

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cernilton
Description: Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
Study: NCT05484687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administer 1.5 mg/kg intravenously to the patient before induction of anesthesia, and continue to infuse 1.5 mg/kg/h during the operation until the end of the operation
Description: Administer 1.5 mg/kg lidocaine
Study: NCT02782078

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Clindamycin and rifampicin dosages
Description: blood samples for clindamycin and rifampicin dosages (for each patient)
Study: NCT04132804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: Tai Chi Chuan (taijiquan) or Tai Chi is a mind-body practice borne of Chinese philosophy and martial arts which has been practiced for centuries to promote deep relaxation, strengthened health, and to prevent injuries and illness.
Study: NCT02571738

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CHAM
Description: The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of Care
Study: NCT04243759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control App Version
Description: The control version is a smartphone-compatible CGNG. The cued go/no-go (CGNG) tests ability to respond fast to go targets (activation) while withholding response to no-go targets (inhibition).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard App Version
Description: The standard version is the same as the control version with the exception that information about performance (correct or incorrect) is displayed along with RT in ms for a correct response during each inter-trial interval.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental, Feedback App Version
Description: The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental, Feedback App Version
Description: The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental, Feedback App Version
Description: The experimental, feedback version includes the standard plus feedback on RT and inhibition errors compared to pre-drinking. The app will state that there are simple alternatives with invitation to press a box to view advice, based on research that risk information may increase risky behavior if convenient options are not given73. Feedback will be worded non-judgmentally per motivational interviewing tenets.
Study: NCT03344835

Intervention type: OTHER
Intervention: No intervention
Study: NCT03991247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized behavioral therapy program delivered by internet for insomnia management
Description: The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized behavioral therapy program delivered by internet for insomnia management
Description: The online program consists in restriction of time in bed and stimulus control instructions.~First, patient will complete an on-line sleep diary during 2 weeks. The personalized program is then activated by a practitioner (phone interview) who both assesses restriction of time in bed and delivers instructions of stimulus control. Then, restriction of time in bed is administered by the internet-delivered self-help program. The participant still completes his on-line sleep diary every day. Every 7 days, according mean sleep efficiency, a new sleep schedule recommendation is given to the participant. In addition, the program delivers everyday a set of instructions (stimulus control) designed to re-associate the bed/bedroom with sleep and to re-establish a consistent sleep wake schedule. The duration of restriction of time in bed program is 3 weeks (during spa treatment or at home depending on the allocated arm).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa treatment
Description: Spa treatment is harmonized in the different stations. It consists in:~* a medical thermal follow-up: weekly medical consultation of 15 minutes during the 3 weeks spa treatment.~* an institutional follow-up: support, help and monitoring of patients during spa treatment~* Crenotherapy: 18 baths of 10 minutes in running water, 18 spa showers of 3 minutes, 9 massages under water of 20 minutes, 18 baths of 10 minutes in pool. Water temperature of pool is between 31°C and 33°C. Water temperature for other care is 35°C and 38°C.
Study: NCT02357433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Doses CPFA
Study: NCT01579864

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: succinylcholine
Description: Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rocuronium
Description: rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
Study: NCT00848432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risperidone
Description: Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
Study: NCT01580098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-monitoring for patients with Diabetes mellitus type 2
Description: Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
Study: NCT03033836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV treatment
Description: Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
Study: NCT02933476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibrotactile Stimulation
Description: The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
Study: NCT04529460

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 antibody point of care test kit
Description: A disponible point of care test that identifies the presence of antibodies to COVID-19

Intervention type: DIAGNOSTIC_TEST
Intervention: COVID-19 antibody point of care test kit
Description: A disponible point of care test that identifies the presence of antibodies to COVID-19
Study: NCT03370302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-228
Description: TAK-228 Capsules.
Study: NCT02465970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STARSTIM
Description: Multifocal transcranial direct current stimulation.~* CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.~* The stimulation is applied during a 60 min session

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham TDCS
Study: NCT03959189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERX-963
Description: Active medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Comparator
Study: NCT00525252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
Study: NCT03915899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WIN (Welcome Incoming Neighbor)
Description: WINs will conduct active community surveillance to rapidly identify and welcome in-migrants, provide them with information about the availability of CHP, utilize a motivational interviewing approach to encourage CHP adoption, refer in-migrants to free services, and follow-up in-migrants to assess and further encourage engagement in CHP.
Study: NCT00525252

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo will be orally administered for 12 consecutive weeks
Study: NCT01302275

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Study: NCT00376506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurostimulation device for dysphagia
Description: A neurostimulation device that is surgically implanted in the swallowing muscles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: External vibrotactile device
Description: A vibrotactile device that is placed on the neck during swallowing.
Study: NCT01302275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxcarbazepine
Description: Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
Study: NCT03836144

Intervention type: DIETARY_SUPPLEMENT
Intervention: Potassium citrate
Study: NCT02112968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proscan
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Zyoptix
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study: NCT03053011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vibrating bracelet
Description: A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
Study: NCT03220789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drilling at low speed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drilling at conventional or high speed
Study: NCT03791372

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: 0.9% Sodium Chloride in control group
Study: NCT02112968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supracor
Description: One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
Study: NCT03446924

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidic Acid
Description: To be administered a single dose of 1.5 g phosphatidic acid in capsule form (250 mg / capsule).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice flour
Description: Rice flour placebo to be administered a single dose of 1.5 g in capsule form (250 mg / capsule).
Study: NCT03791372

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Umbilical Cord Blood
Description: Autologous Umbilical Cord Blood Mononuclear Cells Therapy in Cerebral Palsy for safety and effect evaluation.
Study: NCT01259466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
Study: NCT04403867

Intervention type: PROCEDURE
Intervention: Sentinel lymph node (SLN) biosy +/- lymphadenectomy
Description: Evaluation of type and volume of lymph nodal disease
Study: NCT02363491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPN-305
Description: For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
Study: NCT00766818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra
Description: Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
Study: NCT01837342

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical reserction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiological percutaneous drainage and washing drainage
Study: NCT02513446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: Single dose of BI 1026706 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1026706
Description: Single dose of BI 1026706 on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
Study: NCT03815305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Centella Asiatica Extract
Description: centlla asiatica oral drug at 1100 mg dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical CA
Description: 1% centella asiatica ointment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petroleum jelly
Description: vaseline album
Study: NCT02612155

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of autologous cord blood
Description: Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
Study: NCT02394197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine phosphate
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study: NCT02612155

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
Study: NCT02511353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo for ivermectin.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo for ivermectin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Study: NCT02394197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study: NCT04341571

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Probiotics capsules (lactobacillus acidophilus y bifidobacterium lactis) 400 mg 1 time at day before breakfast and one placebo capsule before dinner during 13 weeks. Homologated to the other intervention.
Study: NCT02511353

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dihydroartemisinin-piperaquine
Study: NCT04341571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin capsules, 750 mg, two pere day before breakfast and dinner during 13 weeks.~Homologated to the other intervention.
Study: NCT04770974

Intervention type: OTHER
Intervention: Biomarkers and proteomics
Description: Biomolecular, proteomic, metabolomic and spectroscopy characterization of urothelial bladder neoplasia, on a 3D culture model (organoid) obtained from bladder tumor tissue
Study: NCT03724344

Intervention type: OTHER
Intervention: Cross section resaerch
Description: Assessment of cognitive (MoCA), mental behavioral symptoms (NPI） the Self-rating Depression Scale (SDS) and the Self-rating Anxiety Scale (SAS).
Study: NCT02448108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-IPSRT
Description: internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT.
Study: NCT02394197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: primaquine
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: primaquine
Description: use at operational doses by age group according to the Mexican guidelines for vector borne diseases
Study: NCT02378805

Intervention type: DRUG
Intervention: ACE-inhibitor
Description: observational study!
Study: NCT01580098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse-monitoring for patients with Diabetes mellitus type 2
Description: Nurses are submitting the vital parameters of the patient via mobile device.
Study: NCT02378805

Intervention type: DRUG
Intervention: ACE-inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: ACE-inhibitor
Description: observational study!
Study: NCT02448108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: i-IPSRT
Description: internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.~CH will have participated in a two day training about Bipolar Disorder and IPSRT.

Intervention type: OTHER
Group type: OTHER
Intervention: Written Psychoeducation
Description: Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
Study: NCT02378805

Intervention type: DRUG
Intervention: ACE-inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: AT1-inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: AT1-inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: AT1-inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: AT1-inhibitor
Description: observational study!

Intervention type: DRUG
Intervention: HMG-Coenzyme inhibitor (statin)
Description: observational study!

Intervention type: DRUG
Intervention: HMG-Coenzyme inhibitor (statin)
Description: observational study!

Intervention type: DRUG
Intervention: HMG-Coenzyme inhibitor (statin)
Description: observational study!
Study: NCT04385992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-Dotatate
Description: Peptide Receptor Radionuclide Therapy (PRRT) is based on specific somatostatin receptor targeting with radiolabelled analogues 90Y-DOTATOC and 177Lu-DOTATATE
Study: NCT00866320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
Study: NCT01614119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Description: Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture